Evidence map›Paper›PMID 33494783›Full record

ArticleCancer cell international2021

Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT.

Yuxin Qi, Wenping Yang, Shuang Liu, Fanjie Han, Haibin Wang, Yonghong Zhao, Yufa Zhou, Daijun Zhou

Abstract read
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuxin QiDepartment of Respiratory Medicine, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, 271199, China.
Wenping YangDepartment of Respiratory Medicine, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, 271199, China.
Shuang LiuDepartment of Respiratory Medicine, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, 271199, China.
Fanjie HanDepartment of Respiratory Medicine, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, 271199, China.
Haibin WangDepartment of Respiratory Medicine, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, 271199, China.
Yonghong ZhaoDepartment of Respiratory Medicine, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, 271199, China.
Yufa ZhouDepartment of Respiratory Medicine, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, 271199, China.
Daijun ZhouDepartment of Oncology, General Hospital of Western Theater Command of PLA, Chengdu, 610083, China. zhoudaijun25418@163.com.ORCID http://orcid.org/0000-0001-5490-4871

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer is one of the important health threats worldwide, of which 5-year survival rate is less than 15%. Non-small-cell lung cancer (NSCLC) accounts for about 80% of all lung cancer with high metastasis and mortality.

methodsCisplatin loaded multiwalled carbon nanotubes (Pt-MWNTS) were synthesized and used to evaluate the anticancer effect in our study. The NSCLC cell lines A549 (cisplatin sensitive) and A549/DDP (cisplatin resistant) were used in our in vitro assays. MTT was used to determine Cancer cells viability and invasion were measured by MTT assay and Transwell assay, respectively. Apoptosis and epithelial-mesenchymal transition related marker proteins were measured by western blot. The in vivo anti-cancer effect of Pt-MWNTs were performed in male BALB/c nude mice (4-week old).

resultsPt-MWNTS were synthesized and characterized by X-ray diffraction, Raman, FT-IR spectroscopy and scan electron microscopy. No significant cytotoxicity of MWNTS was detected in both A549/DDP and A549 cell lines. However, Pt-MWNTS showed a stronger inhibition effect on cell growth than free cisplatin, especially on A549/DDP. We found Pt-MWNTS showed higher intracellular accumulation of cisplatin in A549/DDP cells than free cisplatin and resulted in enhanced the percent of apoptotic cells. Western blot showed that application of Pt-MWNTS can significantly upregulate the expression level of Bax, Bim, Bid, Caspase-3 and Caspase-9 while downregulate the expression level of Bcl-2, compared with free cisplatin. Moreover, the expression level of mesenchymal markers like Vimentin and N-cadherin was more efficiently reduced by Pt-MWNTS treatment in A549/DDP cells than free cisplatin. In vivo study in nude mice proved that Pt-MWNTS more effectively inhibited tumorigenesis compared with cisplatin, although both of them had no significant effect on body weight.

conclusionPt-MWNT reverses the drug resistance in the A549/DDP cell line, underlying its possibility of treating NSCLC with cisplatin resistance.

Indexed as

5-year survival rateChemotherapyEpithelial-mesenchymal transformationNon-small-cell lung cancer

Identifiers

PMID33494783
PMCPMC7836500

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.